MAIA Biotechnology Inc (MAIA)
3.08
+0.19
(+6.57%)
USD |
NYAM |
May 10, 16:00
3.10
+0.02
(+0.65%)
After-Hours: 20:00
MAIA Biotechnology SG&A Expense (Quarterly): 2.660M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 2.660M |
September 30, 2023 | 2.356M |
June 30, 2023 | 2.065M |
March 31, 2023 | 1.988M |
December 31, 2022 | 0.7023M |
September 30, 2022 | 2.752M |
Date | Value |
---|---|
June 30, 2022 | 1.323M |
March 31, 2022 | 1.366M |
December 31, 2021 | 1.491M |
September 30, 2021 | 1.152M |
June 30, 2021 | 0.8593M |
March 31, 2021 | 0.788M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.7023M
Minimum
Dec 2022
2.752M
Maximum
Sep 2022
1.625M
Average
1.429M
Median
SG&A Expense (Quarterly) Benchmarks
Cyclacel Pharmaceuticals Inc | 1.873M |
Avid Bioservices Inc | 6.382M |
Oragenics Inc | 1.754M |
NeuBase Therapeutics Inc | 1.203M |
Viking Therapeutics Inc | 9.97M |